Search Within

MYELODYSPLASTIC SYNDROMES

Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Journal: Current Cancer Therapy Reviews
Volume: 2,Issue: 3
Page: 199-209
Authors: Eyal C. Attar and Karen K. Ballen

Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy

Journal: Current Cancer Therapy Reviews
Volume: 2,Issue: 3
Page: 271-279
Authors: Yong Wang, Virginia Probin and Daohong Zhou

Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers

Journal: Current Medicinal Chemistry
Volume: 13,Issue: 20
Page: 2345-2352
Authors: Y. Oji, H. Sugiyama, I. Kawase, O. A. Elisseeva, H. Nakajima, K. Udaka, M. Kawakami, A. Tsuboi and Y. Oka

Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS

Journal: Current Cancer Drug Targets
Volume: 6,Issue: 6
Page: 553-563
Authors: Hironori Harada, Yuka Harada and Akiro Kimura

Radioimmunotherapy of Non-Hodgkins Lymphomas

Journal: Current Drug Targets
Volume: 7,Issue: 10
Page: 1293-1300
Authors: Bruce D. Cheson

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 315-321
Authors: Claudia I. Muller, Bjorn Ruter, H. Phillip Koeffler and Michael Lubbert

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 339-342
Authors: Vishakha Kale and Alan F. List

Signaling Through RAS-RAF-MEK-ERK: from Basics to Bedside

Journal: Current Medicinal Chemistry
Volume: 14,Issue: 5
Page: 601-623
Authors: Armin Zebisch, Armin P. Czernilofsky, Gyorgy Keri, Julja Smigelskaite, Heinz Sill and Jakob Troppmair

Drug Resistance and Methylation in Myelodysplastic Syndrome

Journal: Current Pharmaceutical Biotechnology
Volume: 8,Issue: 2
Page: 77-81
Authors: D. O. Vidal, L. F. Lopes and E. T. Valera

Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches

Journal: Current Cancer Drug Targets
Volume: 7,Issue: 6
Page: 541-558
Authors: E. D. Warlick and B. D. Smith

Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes

Journal: Current Drug Targets
Volume: 6,Issue: 6
Page: 713-725
Authors: E. H. Lindberg

Inhibition of Raf Kinase in the Treatment of Acute Myeloid Leukemia

Journal: Current Pharmaceutical Design
Volume: 8,Issue: 25
Page: 2243-2248
Authors: Michael Crump

Vitamin D Analogs: Mechanism of Action and Therapeutic Applications

Journal: Current Medicinal Chemistry
Volume: 8,Issue: 13
Page: 1661-1679
Authors: Sunil Nagpal, Jianfen Lu and Marcus F. Boehm

Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Journal: Current Genomics
Volume: 1,Issue: 2
Page: 153-173
Authors: S. K. Ma and T. S.K. Wan

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 13
Page: 1274-1287
Authors: Giuseppe Leone, Francesco D'Alo, Giuseppe Zardo, Maria Teresa Voso and Clara Nervi

New Pharmacological Concepts for the Treatment of Iron Overload Disorders

Journal: Current Medicinal Chemistry
Volume: 16,Issue: 5
Page: 576-590
Authors: Sabine M. Mair and Guenter Weiss

Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases

Journal: Current Medicinal Chemistry
Volume: 16,Issue: 17
Page: 2075-2085
Authors: Tamer E. Fandy

The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials

Journal: Current Cancer Therapy Reviews
Volume: 5,Issue: 4
Page: 243-255
Authors: Hanne Fredly, Elisabeth Ersvaer, Camilla Stapnes, Bjorn Tore Gjertsen and Oystein Bruserud

Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS

Journal: Current Cancer Therapy Reviews
Volume: 5,Issue: 4
Page: 310-314
Authors: A. Mario Marcondes, Aravind Ramakrishnan and H. Joachim Deeg

Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways

Journal: Current Cancer Drug Targets
Volume: 10,Issue: 5
Page: 539-545
Authors: S. Cang, Q. Lu, Y. Ma and D. Liu

Update on MDS Therapy: From Famine to Feast

Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 8,Issue: 4
Page: 187-198
Authors: Preeti Chaudhary and Chirag Shah

Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 7
Page: 837-848
Authors: Anna Szmigielska-Kaplon and Tadeusz Robak

Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome

Journal: Current Molecular Medicine
Volume: 11,Issue: 8
Page: 678-685
Authors: H. Nagoshi, S. Horiike, J. Kuroda and M. Taniwaki

Antiangiogenesis in Myelodysplastic Syndrome

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 9
Page: 1044-1052
Authors: A. Aguayo, F. M. Armillas-Canseco and D. Martinez-Banos


Review: Recent Clinical Trials in Epigenetic Therapy

Journal: Reviews on Recent Clinical Trials
Volume: 1,Issue: 2
Page: 169-182
Authors: Yasuhiro Oki and Jean-Pierre J. Issa

Novel Purine Nucleoside Analogues for Hematological Malignancies

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 3,Issue: 2
Page: 123-136
Authors: Anna Korycka, Ewa Lech-Maranda and Tadeusz Robak

Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes

Journal: Current Stem Cell Research & Therapy
Volume: 6,Issue: 2
Page: 122-130
Authors: Maria-Christina Kastrinaki, Charalampos Pontikoglou, Mirjam Klaus, Emily Stavroulaki, Konstantia Pavlaki and Helen A. Papadaki

Posaconazole: A New Antifungal Weapon

Journal: Reviews on Recent Clinical Trials
Volume: 6,Issue: 3
Page: 204-219
Authors: Georgios Aperis and Polichronis Alivanis

Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms

Journal: Medicinal Chemistry Reviews - Online (Discontinued)
Volume: 2,Issue: 6
Page: 447-454
Authors: Y. Oka, A. Tsuboi, O. A. Elisseeva, H. Nakajima, Y. Oji and H. Sugiyama


Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 13
Page: 1751-1754
Authors: Matilde Y. Follo, Sara Mongiorgi, Carlo Finelli, Manuela Piazzi, Irene Faenza, Giulia Ramazzotti, Patrizia Santi, James A. McCubrey, Alberto M. Martelli and Lucio Cocco

Editorial [Hot Topic: New Treatment Strategy of the Myelodysplastic Syndromes]

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3147-3148
Authors: Kaoru Tohyama

World Health Organization Classification of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3149-3162
Authors: Magdalena Czader and Attilio Orazi

Genome-wide Analysis of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3163-3169
Authors: Masashi Sanada and Seishi Ogawa

Implication of microRNAs in the Pathogenesis of MDS

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3170-3179
Authors: Jing Fang, Melinda Varney and Daniel T. Starczynowski

Immunosuppressive Therapy for Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3184-3189
Authors: Christiane Dobbelstein and Arnold Ganser

Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3190-3197
Authors: Kaoru Tohyama

Lenalidomide for Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3198-3203
Authors: Rami S. Komrokji and Alan F. List

Approach to New Therapeutics: Investigation by the Use of MDS-derived Cell Lines

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3204-3214
Authors: Takayuki Tsujioka, Akihito Matsuoka, Yumi Tohyama and Kaoru Tohyama

Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS

Journal: Current Pharmaceutical Design
Volume: 18,Issue: 22
Page: 3222-3234
Authors: Norbert Gattermann

Significance of Genome-Wide Analysis of Copy Number Alterations and UPD in Myelodysplastic Syndromes using Combined CGH – SNP Arrays

Journal: Current Medicinal Chemistry
Volume: 19,Issue: 22
Page: 3739-3747
Authors: Ausaf Ahmad and M. Anwar Iqbal

Demethylating Agents as Epigenetic Anticancer Therapeutics

Journal: Current Cancer Therapy Reviews
Volume: 9,Issue: 1
Page: 24-33
Authors: Arash Nabbi, Shankha Satpathy and Karl Riabowol

Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 6
Page: 661-669
Authors: Massimo Martino, Roberta Fedele, Tiziana Moscato and Francesca Ronco

How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments

Journal: Current Pharmaceutical Design
Volume: 19,Issue: 30
Page: 5362-5373
Authors: Thomas Cluzeau, Guillaume Robert, Arnaud Jacquel and Patrick Auberger

Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 8
Page: 895-904
Authors: Caroline Hinton, Helma Antony, Saeed M. Hashimi, Alan Munn and Ming Q. Wei

MicroRNA Dysregulation in the Myelodysplastic Syndromes

Journal: MicroRNA
Volume: 2,Issue: 3
Page: 174-186
Authors: Stephen S. Chung and Christopher Y. Park

Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes

Journal: Current Bioinformatics
Volume: 9,Issue: 4
Page: 408-413
Authors: Giorgio Bianciardi and Pietro Luzi

Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 14,Issue: 11
Page: 873-883
Authors: Lucia Manzoli, Sara Mongiorgi, Cristina Clissa, Carlo Finelli, Anna Maria Billi, Alessandro Poli, Marilisa Quaranta, Lucio Cocco and Matilde Y. Follo

Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing

Journal: Current Gene Therapy
Volume: 15,Issue: 4
Page: 416-427
Authors: Ulrich Siler, Anna Paruzynski, Heidi Holtgreve-Grez, Elena Kuzmenko, Ulrike Koehl, Eleonore D. Renner, Canan Alhan, Arjan A. van de Loosdrecht, Joachim Schwäble, Thomas Pfluger, Joelle Tcinda9, Markus Schmugge, Anna Jauch, Sonja Naundorf, Klaus Kühlcke, Gundula Notheis, Tayfun Güngör, Christof V. Kalle, Manfred Schmidt, Manuel Grez, Reinhard Seger and Janine Reichenbach*

The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions

Journal: Current Diabetes Reviews
Volume: 12,Issue: 3
Page: 231-239
Authors: Eyad Hamoudeh, Amer M. Zeidan, Lisa Barbarotta and Nina Rosano

Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 15,Issue: 2
Page: 148-161
Authors: Evgenia Verigou, Polixeni Lampropoulou, Nikoletta Smyrni, Georgia Kolliopoulou, George Sakellaropoulos, Ioannis Starakis, Panagiotis Zikos, Elena Solomou, Argiris Symeonidis and Marina Karakantza

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2333-2344
Authors: Bon Ham Yip, Hamid Dolatshad, Swagata Roy, Andrea Pellagatti and Jacqueline Boultwood

Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2323-2332
Authors: Anna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, Lorenz C. Hofbauer and Uwe- Platzbecker

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 22,Issue: 16
Page: 2349-2357
Authors: Carlo Finelli, Matilde Y. Follo, Marta Stanzani, Sarah Parisi, Cristina Clissa, Sara Mongiorgi, Marilena Barraco and Lucio Cocco

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 16,Issue: 16
Page: 1344-1358
Authors: Jiao Chen, Jie Yang and Peng Cao

Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes

Journal: Current Pharmaceutical Design
Volume: 23,Issue: 1
Page: 135-169
Authors: Karmen Stankov, Suncica Stankov and Jasmina Katanic

Eryptosis: Ally or Enemy

Journal: Current Medicinal Chemistry
Volume: 24,Issue: 9
Page: 937-942
Authors: Marilena Briglia, Maria Antonia Rossi and Caterina Faggio*

Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes

Journal: Current Cancer Drug Targets
Volume: 17,Issue: 7
Page: 586-602
Authors: Bani Bandana Ganguly*

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer

Journal: Current Topics in Medicinal Chemistry
Volume: 18,Issue: 6
Page: 505-524
Authors: Horrick Sharma*

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 18,Issue:
Page: 1-28
Authors: Ota Fuchs*